NewAmsterdam Pharma Company NAMS Noncash Rent Expense
Noncash Rent Expense at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept nams:NoncashRentExpense.
The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about NewAmsterdam Pharma Company's noncash rent expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NewAmsterdam Pharma Company's noncash rent expense?
- NewAmsterdam Pharma Company (NAMS) reported noncash rent expense of -$16K in Q1 2026.
- How has NewAmsterdam Pharma Company's noncash rent expense changed year-over-year?
- NewAmsterdam Pharma Company's noncash rent expense decreased by 633.3% year-over-year, from $3K to -$16K.
- What is the long-term trend for NewAmsterdam Pharma Company's noncash rent expense?
- Over 3 years (2021 to 2024), NewAmsterdam Pharma Company's noncash rent expense has grown at a 81.7% compound annual growth rate (CAGR), from $2K to $12K.
- What does noncash rent expense mean?
- This represents the non-cash portion of lease expenses recognized in the operating section of the cash flow statement. It reflects the amortization of right-of-use assets or similar lease-related accounting adjustments that do not involve an actual cash outflow. Investors use this to reconcile net income with operating cash flow by removing non-cash accounting impacts.